Medical Services Cancer Care Clinical Research Find a Location Find a Doctor Cancer Care Menu About Our Cancer Care Program Your Cancer Care Team Your First Visit Breast Cancer Cancer Care Cancer Treatments DigniCap Scalp Cooling System Radiation Therapy Center for Precision Medicine and Genomic Health BRCA Testing Hereditary Cancer Program Proactive Genetic Screening Clinical Research Palliative Care Patient Testimonials Resources Cancer Resource Center Clinical & Support Services Frequent Numbers Specialty Cancer Care Clinics Cardio-Oncology Neuro-oncology Tristate Gynecological Oncology Tobacco Cessation E-cigarette Education Freshstart Tobacco Cessation Nicotine Medication Nicotine Replacement Nicotine Therapy Saving on Medication Success Stories Tobacco Cessation Resources Our Commitment The physicians at St. Elizabeth Healthcare are committed to providing the best and most current medical care for all patients. Through this commitment, our patients are eligible for participation in research trials sponsored by the National Cancer Institute and members of the NCI National Clinical Trials Network (NCTN). For questions or additional information about clinical research trials, please contact an Oncology Research Team Member: Kim Schmidt, RN Phone: (859) 301-9418 Kimberly.Schmidt@stelizabeth.com Ellen Burns, CRC Phone: (859) 301-4726 Ellen.Burns@stelizabeth.com Becky Dixon, RN Phone: (859) 301-5473 Becky.Dixon@stelizabeth.com Tara Terrell, CRC Phone: (859) 301-4737 Tara.Terrell@stelizabeth.com Hannah Ingraham, RN Phone: (859) 301-4046 Hannah.Ingraham@stelizabeth.com Carissa Stamper, CRC Phone: (859) 301-4037 Carissa.Stamper@stelizabeth.com Clinical Research Trials Open to Patients at St. Elizabeth Healthcare Anticoagulation AFT-28 (CANVAS) – Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) – Contact: Tara Terrell, CRC ACCRU-SC-1601 – A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy – Contact: Hannah Ingraham, RN Breast Cancer ER-/PR-/HER2- ECOG-ACRIN - EA1131 – A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy – Contact: Tara Terrell, CRC NRG-BR003 – A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer – Contact: Tara Terrell, CRC DCIS AFT-25 (COMET) – Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial – Contact: Kim Schmidt, RN NWU2015-06-04 – Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast – Contact: Kim Schmidt, RN Breast Radiation NSABP B-51 – A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest-wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy – Contact: Sara Cahill, CRC ALLIANCE - A221505 – Phase III Randomized Trial of Hyprofractionated Post Mastectomy Radiation With Breast Reconstruction – Contact: Sara Cahill, CRC Tailor RT/CCTG MA.39 – A Randomized Phase III Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer using Oncotype Score – Contact: Sara Cahill, CRC Breast - Quality of Life ALLIANCE - A011502 (ABC) – Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy – Contact: Tara Terrell, CRC Endometrial Cancer NRG-GY012 – A randomized Phase II study comparing single-agent Olaparib, single-agent Cediranib, and the combination of Cediranib/Olaparib in women with recurrent, persistent, or metastatic endometrial cancer – Contact: Becky Dixon, RN NRG-GY014 – A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma— Contact: Becky Dixon, RN GI Cancer ALLIANCE - A021502 (ATOMIC) – Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC) – Contact: Hannah Ingraham, RN S0820 (PACES) – A Double Blind Placebo-controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Secondary Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) – Contact: Hannah Ingraham, RN AM0010 (Pancreatic) – A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen – Contact: Hannah Ingraham, RN Lung Cancer Non-Small Cell ALCHEMIST (A151216) – Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery, Followed by Treatment Arms A081105 (Erlotinib), E4512 (Crizotinib), and EA5142 (Nivolumab) – Contact: Ellen Burns, CRC NRG-LU002 – Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial — Contact: Ellen Burns, CRC NRG-LU004 (ARCHON-1) – Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1) – Contact: Ellen Burns, CRC Next Generation Sequencing (NGS) ACCRU-2018-01 Solid Tumor – Blood Sample Collection to Evaluate Biomarkers in Subjects with untreated primary malignancy of breast, lung, colorectal, prostate, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian or esophageal cancer – Contact: Carissa Stamper, CRC ACCRU-2018-02 Hematologic Malignancies – Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Hematologic Malignancies – Contact: Carissa Stamper, CRC ACCRU-2018-03 Melanoma – Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Melanoma – Contact: Carissa Stamper, CRC Paradigm Registry – A Prospective Study to Evaluate the Efficacy of Precision Molecular Testing in the Treatment of Advanced Solid Tumors— Contact: Carissa Stamper, CRC Ovarian Cancer NRG-GY009 – A Randomized Phase II/III Trial investigating how well Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab will work in treating patients with recurrent Ovarian, Fallopian Tube, or primary Peritoneal Cancer – Contact: Becky Dixon, RN Uterine Cancer GOG-0238 – A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus – Contact: Becky Dixon, RN NRG-GY005 – A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)— Contact: Becky Dixon, RN Additional Resources We encourage patients to explore additional information about clinical trials provided by the National Cancer Institute or the American Cancer Society. Also, The American Cancer Society provides a free, confidential Clinical Trials Matching Service that helps patients, their families and health care workers find cancer clinical trials most appropriate to a patient's medical and personal situation. Follow this NIH Clinical Research Trials and You link for information about the risks and benefits of taking part in a clinical trial, how to find a trial, and questions to ask when considering participation in a trial. Clinical Trials As First Line of Treatment Hear from Amy Bolton, Nurse Manager for the Clinical Research Institute discuss how clinical trials may be a good treatment option. WATCH HERE Award-Winning Program St. Elizabeth received the 2017 and 2018 National Clinical Trial Network High Performing Site Award from the National Cancer Institute for having both a high number of patients enrolled in cancer clinical trials and high-level quality data.